Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:29 2024-06-10 am EDT			5-day change	1st Jan Change
7.25 ^GBX	0.00%		+3.57%	-17.14%

Jun. 07	Ondine Biomedical loss narrows as revenue soars 88% in 2023	AN
Jun. 07	AIM WINNERS & LOSERS: Corcel receives approvals for data acquisition	AN

Ondine Biomedical says commercial progress ahead of forecast

March 15, 2024 at 04:48 pm EDT

Ondine Biomedical Inc - Vancouver-based life sciences company - Announces significant commercial progress to date in 2024, ahead of management's expectations. Says Ondine's Steriwave technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures.

Current stock price: 9.64 pence, up 4.2% in London on Friday

12-month change: down 48%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Ondine Biomedical Inc.

Ondine Biomedical loss narrows as revenue soars 88% in 2023	Jun. 07	AN
AIM WINNERS & LOSERS: Corcel receives approvals for data acquisition	Jun. 07	AN
Correction: -- Earnings Flash (OBI.L) ONDINE BIOMEDICAL Reports FY23 Loss CA$-0.07	Jun. 07	MT
Earnings Flash (OBI.L) ONDINE BIOMEDICAL Posts FY23 Revenue CA$1.2M	Jun. 07	MT
Earnings Flash (OBI.L) ONDINE BIOMEDICAL Reports FY23 Loss $-0.07	Jun. 07	MT
Ondine Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Jun. 07	CI
Hellenic Dynamics and Ondine Biomedical raise funds	May. 08	AN
Ondine Biomedical shares rise on fundraise to advance Steriwave	May. 03	AN
Ondine Biomedical to Raise GBP3 Million Via Placing, Subscription	May. 03	MT
EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles	Apr. 24	AN
Ondine Biomedical celebrates use of Steriwave in Australian hospital	Apr. 22	AN
Mater Hospital, to Use Ondine Biomedical's Award-Winning Light-Activated Antimicrobial Technology	Apr. 22	CI
Ondine Biomedical's Steriwave reduces SSI's by 32%, study shows	Apr. 15	AN
Ondine Biomedical shares jump as Steriwave approved by HCA Healthcare	Apr. 10	AN
HCA Healthcare UK Approves the Steriwave Light-Activated Antimicrobial Developed by Ondine Biomedical Inc	Apr. 10	CI
Ondine says introduction of Steriwave in ICU market could boost sales	Apr. 04	AN
Ondine Biomedical Inc. Prepares to Enter the Intensive Care Unit Market	Apr. 04	CI
Ondine Biomedical's Finance Chief Resigns; Interim CFO Named	Mar. 28	MT
Ondine Biomedical appoints new interim chief financial officer	Mar. 28	AN
Ondine Biomedical Inc. Announces Executive Appointments	Mar. 28	CI
Ondine Biomedical Inc. Announces Chief Financial Officer Changes	Mar. 28	CI
Peel Hunt's RetailBook raises GBP2.5 million	Mar. 25	AN
Ondine Biomedical Wins First NHS Commercial Deal for Steriwave Treatment	Mar. 25	MT
Ondine Biomedical Inc. Announces Steriwave Study Shows 77% Drop in Antibody Use	Mar. 21	CI
Ondine Biomedical says commercial progress ahead of forecast	Mar. 15	AN

Chart Ondine Biomedical Inc.

Duration

Period

More charts

Company Profile

Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-28 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Ondine Biomedical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0725 GBP

Average target price

0.55 GBP

Spread / Average Target

+658.62%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ONDINE BIOMEDICAL INC.	-17.14%	25.58M
ABBOTT LABORATORIES	-2.34%	187B
MEDTRONIC PLC	+0.92%	110B
BECTON, DICKINSON AND COMPANY	-1.77%	69.54B
CENCORA, INC.	+14.21%	46.37B
DEXCOM, INC.	-6.06%	46.05B
HOYA CORPORATION	+7.97%	42.54B
METTLER-TOLEDO INTERNATIONAL, INC.	+19.03%	30.72B
TERUMO CORPORATION	+17.70%	25.62B
ZIMMER BIOMET HOLDINGS, INC.	-7.25%	23.32B

Other Medical Equipment, Supplies & Distribution